• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Bioorg Chem . Discovery of adamantane-based α-hydroxycarboxylic acid derivatives as potent M2-S31N blockers of influenza A virus

tetano

Editor, Senior Moderator
Bioorg Chem


. 2025 Oct 23:166:109124.
doi: 10.1016/j.bioorg.2025.109124. Online ahead of print. Discovery of adamantane-based α-hydroxycarboxylic acid derivatives as potent M2-S31N blockers of influenza A virus

Jianghong Dong[SUP] 1 [/SUP], Changjuan Chen[SUP] 2 [/SUP], Xin Sun[SUP] 2 [/SUP], Qinglan Pei[SUP] 2 [/SUP], Panpan Wang[SUP] 2 [/SUP], Miao Yu[SUP] 2 [/SUP], Enming Du[SUP] 3 [/SUP]



Affiliations
Abstract

The clinical discontinuation of amantadine and rimantadine due to widespread drug resistance highlights the need for new chemical entities that target the M2 ion channel to fight influenza outbreaks and pandemics. Based on the resistance mechanism of adamantane-based drugs and the crystal structure of the S31N mutant, we have designed and synthesized a series of adamantane-based α-hydroxycarboxylic acid derivatives using the molecular hybridization principle and induced fit docking studies. Their biological assays were performed on the wild-type influenza A virus A/HK/68 (H3N2) and adamantane-resistant A/M2-S31N mutant viruses A/WSN/33 (H1N1) were tested in vitro. Among them, the most potent compound 3p showed dual inhibitory activity against both the wild-type and the drug-resistant mutant viruses, with EC[SUB]50[/SUB] values of 0.92 μM and 0.55 μM, respectively. Its activity was comparable to that of oseltamivir. Additionally, this compound had a higher selectivity index (SI = 651). Notably, compound 3p, as a proven M2-S31N blocker, strongly bound to the drug-binding sites through hydrophobic interactions, three π-π interactions, two hydrogen bonds, and a cation-π interaction. Furthermore, the ADMET properties were calculated using the QikProp of the Schrödinger suite, which showed desirable pharmacokinetic characteristics for further development. This work expands the chemical space of adamantane-based compounds and opens up a new direction for the development of anti-influenza drugs with diverse structures.

Keywords: Adamantane derivatives; Anti-influenza activity; Drug resistance; M2 ion channel; Synthesis.

 
Back
Top